Ocular Therapeutix Inc. (OCUL)

4.48
NASDAQ : Health Technology
Prev Close 4.21
Day Low/High 4.29 / 4.68
52 Wk Low/High 2.35 / 8.24
Avg Volume 670.90K
Exchange NASDAQ
Shares Outstanding 42.84M
Market Cap 180.34M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial Of OTX-TP For The Treatment Of Glaucoma

Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial Of OTX-TP For The Treatment Of Glaucoma

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from the first pivotal...

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 16.15 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Reports First Quarter 2019 Financial Results And Business Update

Ocular Therapeutix™ Reports First Quarter 2019 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter...

Ocular Therapeutix™ To Report First Quarter 2019 Financial Results

Ocular Therapeutix™ To Report First Quarter 2019 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended...

Ocular Therapeutix Announces DEXTENZA® (dexamethasone Ophthalmic Insert) Recommended For Unique J-Code By CMS

Ocular Therapeutix Announces DEXTENZA® (dexamethasone Ophthalmic Insert) Recommended For Unique J-Code By CMS

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services...

First Week Of December 20th Options Trading For Ocular Therapeutix (OCUL)

First Week Of December 20th Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ocular Therapeutix, Inc. Settles Litigation With Mati Therapeutics, Inc.

Ocular Therapeutix, Inc. Settles Litigation With Mati Therapeutics, Inc.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has settled litigation with Mati...

Ocular Therapeutix™ To Present New Data At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting And At The American Society Of Cataract And Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix™ To Present New Data At The Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting And At The American Society Of Cataract And Refractive Surgery (ASCRS) Symposium

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced abstracts from its clinical and preclinical...

Ocular Therapeutix™ Reports Changes To Board Of Directors

Ocular Therapeutix™ Reports Changes To Board Of Directors

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced the nomination of Seung Suh (Stanley) Hong, Ph.

Ocular Therapeutix™ To Present At The H.C. Wainwright Global Life Sciences Conference

Ocular Therapeutix™ To Present At The H.C. Wainwright Global Life Sciences Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief...

Ocular Therapeutix™ Announces Notification Of FDA Acceptance Of Supplemental New Drug Submission For DEXTENZA® (dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™ Announces Notification Of FDA Acceptance Of Supplemental New Drug Submission For DEXTENZA® (dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.

Ocular Therapeutix™ Reports Election Of Leslie Williams To Board Of Directors

Ocular Therapeutix™ Reports Election Of Leslie Williams To Board Of Directors

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the election of Leslie J.

Ocular Therapeutix™ To Host 2019 Research & Development Day

Ocular Therapeutix™ To Host 2019 Research & Development Day

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will host a Research & Development...

First Week Of May 17th Options Trading For Ocular Therapeutix (OCUL)

First Week Of May 17th Options Trading For Ocular Therapeutix (OCUL)

Investors in Ocular Therapeutix Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2018 Financial Results And Business Update

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2018 Financial Results And Business Update

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter...

Ocular Therapeutix™ To Present At The Cowen And Company 39th Annual Health Care Conference

Ocular Therapeutix™ To Present At The Cowen And Company 39th Annual Health Care Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Michael Goldstein, M.

Ocular Therapeutix™ To Report Fourth Quarter And Year End 2018 Financial Results

Ocular Therapeutix™ To Report Fourth Quarter And Year End 2018 Financial Results

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and...

Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing

Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a note purchase...

Ocular Therapeutix™ Announces Dosing Of First Patient In OTX-TKI (tyrosine Kinase Inhibitor Implant) Phase 1 Clinical Trial For The Treatment Of Wet Age-related Macular Degeneration (AMD)

Ocular Therapeutix™ Announces Dosing Of First Patient In OTX-TKI (tyrosine Kinase Inhibitor Implant) Phase 1 Clinical Trial For The Treatment Of Wet Age-related Macular Degeneration (AMD)

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the dosing of the first patient in a Phase...

OCUL: Insiders Vs. Shorts

OCUL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 01/31/2019 settlement date, and Ocular Therapeutix Inc is one of the most shorted stocks of the Russell 3000, based on 17.05 "days to cover" versus the median component at 4.98. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) For DEXTENZA® (dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) For DEXTENZA® (dexamethasone Ophthalmic Insert) For The Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the submission of a supplemental New Drug...

Interesting OCUL Call Options For February 15th

Interesting OCUL Call Options For February 15th

Investors in Ocular Therapeutix Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCUL options chain for the new February 15th contracts and identified the following call contract of particular interest.

Ocular Therapeutix™ Announces Completion Of Debt Refinancing

Ocular Therapeutix™ Announces Completion Of Debt Refinancing

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has closed a refinancing of its...

Ocular Therapeutix™ Added To Nasdaq Biotechnology Index

Ocular Therapeutix™ Added To Nasdaq Biotechnology Index

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has been selected for addition to...

Ocular Therapeutix™ Announces The Hiring Of Chad Brines, Vice President, Sales

Ocular Therapeutix™ Announces The Hiring Of Chad Brines, Vice President, Sales

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the hiring of Chad Brines as Vice...

Ocular Therapeutix™ Announces FDA Approval Of DEXTENZA® For The Treatment Of Ocular Pain Following Ophthalmic Surgery

Ocular Therapeutix™ Announces FDA Approval Of DEXTENZA® For The Treatment Of Ocular Pain Following Ophthalmic Surgery

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.

Ocular Therapeutix Breaks Above 200-Day Moving Average - Bullish For OCUL

Ocular Therapeutix Breaks Above 200-Day Moving Average - Bullish For OCUL

In trading on Friday, shares of Ocular Therapeutix Inc crossed above their 200 day moving average of $6.30, changing hands as high as $6.88 per share. Ocular Therapeutix Inc shares are currently trading up about 12% on the day.

TheStreet Quant Rating: D- (Sell)